169 related articles for article (PubMed ID: 35091270)
1. Plasma cell leukemia: Retrospective review of cases at Monter Cancer Center/Northwell Health Cancer Institute, 2014-2019.
Cotte C; Hartley-Brown M
Curr Probl Cancer; 2022 Jun; 46(3):100831. PubMed ID: 35091270
[TBL] [Abstract][Full Text] [Related]
2. Current use of monoclonal antibodies in the treatment of multiple myeloma.
Varga C; Maglio M; Ghobrial IM; Richardson PG
Br J Haematol; 2018 May; 181(4):447-459. PubMed ID: 29696629
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
4. Plasma Cell Leukemia – the Forgotten Disease.
Žárska M; Vrábel D; Bezdekova R; Štork M; Jarošová M; Adam Z; Krejčí M; Pour L; Ševčíková S
Klin Onkol; 2019; 32(1):40-46. PubMed ID: 30764628
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.
Nishihori T; Abu Kar SM; Baz R; Alsina M; Harousseau JL; Kharfan-Dabaja MA
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1144-51. PubMed ID: 23416092
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
8. Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
Ganzel C; Rouvio O; Avivi I; Magen H; Jarchowsky O; Herzog K; Cohen Y; Tadmor T; Horwitz NA; Leiba M; Nagler A; Cohen Y; Bulvik S; Polliack A; Rowe JM; Gatt ME;
Leuk Res; 2018 May; 68():9-14. PubMed ID: 29501828
[TBL] [Abstract][Full Text] [Related]
9. Plasma cell leukemia: Single institution experience.
Babu KG; Jacob LA; Agarwal A; Lakshmaiah KC; Lokanatha D; Suresh Babu MC; Rajeev LK; Lokesh KN; Rudresha AH
Indian J Cancer; 2016; 53(4):619-620. PubMed ID: 28485366
[TBL] [Abstract][Full Text] [Related]
10. The real-world outcomes of multiple myeloma patients treated with daratumumab.
Szabo AG; Klausen TW; Levring MB; Preiss B; Helleberg C; Breinholt MF; Hermansen E; Gjerdrum LMR; Bønløkke ST; Nielsen K; Kjeldsen E; Iversen KF; Teodorescu EM; Dokhi M; Kurt E; Strandholdt C; Andersen MK; Vangsted AJ
PLoS One; 2021; 16(10):e0258487. PubMed ID: 34644367
[TBL] [Abstract][Full Text] [Related]
11. Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party.
Jung SH; Kim K; Yoon SE; Moon JH; Kim D; Kim HJ; Kim MK; Kim KH; Lee HJ; Lee JH; Kim SH; Yoo KH; Lee JH; Lee JJ
Blood Cancer J; 2022 Nov; 12(11):157. PubMed ID: 36404323
[TBL] [Abstract][Full Text] [Related]
12. Plasma cell leukemia.
Albarracin F; Fonseca R
Blood Rev; 2011 May; 25(3):107-12. PubMed ID: 21295388
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell leukemia.
Hayman SR; Fonseca R
Curr Treat Options Oncol; 2001 Jun; 2(3):205-16. PubMed ID: 12057120
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
[TBL] [Abstract][Full Text] [Related]
15. Current and prospective antibody-based therapies in multiple myeloma.
Bryer E; DeStefano C; Kazandjian D
Semin Oncol; 2022 Feb; 49(1):41-47. PubMed ID: 34996619
[TBL] [Abstract][Full Text] [Related]
16. Secondary plasma cell leukaemia treated with single agent venetoclax.
Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
[No Abstract] [Full Text] [Related]
17. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
18. Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy.
Ueno T; Sugio Y; Ohta T; Uehara Y; Ohno Y
Int J Hematol; 2021 Jun; 113(6):941-944. PubMed ID: 33483877
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
[TBL] [Abstract][Full Text] [Related]
20. Two cases of nonsecretory multiple myeloma presenting as primary plasma cell leukemia.
Takahashi T; Kanno S; Itoh H; Yoshimoto M; Tsujisaki M; Fujino M
Intern Med; 2014; 53(18):2121-5. PubMed ID: 25224200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
